ArticleFrontiers in molecular biosciences2021
Pan-Cancer Analysis Identified CD93 as a Valuable Biomarker for Predicting Patient Prognosis and Immunotherapy Response.
Article in Frontiers in molecular biosciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 18 citations in OpenAlex.
- Serum CD93 as a Potential Diagnostic Biomarker for Endometrial Cancer: A Case-Control Study.Journal of clinical medicine · 2026Article
- Targeting neuroplasticity in old brain: restoring synapse with cognitive strategies.Biogerontology · 2026Review
- A preliminary exploration of the role and mechanisms of CD93 in promoting the malignant progression of head and neck squamous cell carcinoma.Frontiers in pharmacology · 2026Article
- Molecular Dynamics Simulations and Their Novel Applications in Drug Delivery for Cancer Treatment: A Review.Annals of biomedical engineering · 2025Review
- Adhesion to aggression: unravelling sLeClinical & experimental metastasis · 2025Review
- CD93 in Health and Disease: Bridging Physiological Functions and Clinical Applications.International journal of molecular sciences · 2025Review
- Analysis of immune status and prognostic model incorporating lactate metabolism and immune-related genes in clear cell renal cell carcinoma.Discover oncology · 2025Article
- Expression and prognostic significance of CD93 in blood vessels in colorectal cancer: an immunohistochemical analysis of 134 cases.BMC gastroenterology · 2025Article
- Exercise Induced Endothelial Mesenchymal Transition (EndMT) Facilitates Meniscal Fibrocartilage Regeneration.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Group XIV C-type lectins: emerging targets in tumor angiogenesis.Angiogenesis · 2024Review
- Vascular Smooth Muscle Cells Transdifferentiate into Chondrocyte-Like Cells and Facilitate Meniscal Fibrocartilage Regeneration.Research (Washington, D.C.) · 2024Article
- Role of CD93 in Health and Disease.Cells · 2023Review
- Prognostic value of neutrophil extracellular trap signature in clear cell renal cell carcinoma.Frontiers in oncology · 2023Article
- CD93 overexpresses in liver hepatocellular carcinoma and represents a potential immunotherapy target.Frontiers in immunology · 2023Article
- Extracellular vesicle-based checkpoint regulation and immune state in cancer.Medical oncology (Northwood, London, England) · 2022Review
- Identify the immune characteristics and immunotherapy value of CD93 in the pan-cancer based on the public data sets.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.